ScoreComparison
Why is Lipella Pharmaceuticals, Inc. ?
Unrated Stock - No Analysis Available
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-80.20%
EBIT Growth (5y)
-155.73%
EBIT to Interest (avg)
-1.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.14%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.54
EV to EBIT
0.19
EV to EBITDA
0.19
EV to Capital Employed
1.00
EV to Sales
-1.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
541.00%
ROE (Latest)
-358.28%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at -107 %
DEBTORS TURNOVER RATIO(HY)
Highest at 25.08 times
OPERATING PROFIT(Q)
Highest at USD -1.27 MM
PRE-TAX PROFIT(Q)
Highest at USD -1.25 MM
NET PROFIT(Q)
Highest at USD -1.25 MM
EPS(Q)
Highest at USD -0.28
-12What is not working for the Company
NET SALES(HY)
At USD 0.09 MM has Grown at -60%
OPERATING CASH FLOW(Y)
Lowest at USD -4.78 MM
RAW MATERIAL COST(Y)
Grown by 101.02% (YoY
Here's what is working for Lipella Pharmaceuticals, Inc.
Operating Profit
Highest at USD -1.27 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -1.25 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -1.25 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.28
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -107 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 25.08 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Lipella Pharmaceuticals, Inc.
Net Sales
At USD 0.09 MM has Grown at -60%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Operating Cash Flow
Lowest at USD -4.78 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Raw Material Cost
Grown by 101.02% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
